MUSK and myasthenia gravis: Finally, besides variable antibody titers, the differences in disease outcomes observed between MuSK-MG models may be attributed to differences in responses to passive immunization with human anti-MuSK-MG antibodies versus active immunization with recombinant MuSK ectodomains.